Therapeutic options in the management of acromegaly: Focus on lanreotide Autogel®

Biologics: Targets and Therapy

Volumn 2, Issue 3, 2008, Pages 463-479

  Roelfsema, Ferdinand ^a   Biermasz, Nienke R ^a   Pereira, Alberto M ^a   Romijn, Johannes A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acromegaly; Growth hormone; Lanreotide; Pegvisomant; Somatostatin analog

Indexed keywords

EID: 68649087646     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s3356     Document Type: Review

References (192)

1. Abe T, Lüdecke DK. 2001. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol, 145:137-45.
2. Abrams P, Alexopoulou O, Abs R, et al. 2007. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol, 157:571-7.
3. Abs R, Verhelst J, Maiter D, et al. 1998. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab, 83:374-8.
4. Ahmed S, Elsheikh M, Stratton IM, et al. 1999. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf), 50:561-7.
5. Alexander L, Appleton D, Hall R, et al.1980. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf), 12:71-9.
6. Alexopoulou O, Abrams P, Verhelst J, et al. 2004. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol, 151:317-24.
7. al-Maskari M, Gebbie J, Kendall-Taylor P. 1996. The effect of a new slowrelease, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin Endocrinol (Oxf), 45:415-21.
8. Amato G, Mazziotti G, Rotondi M, et al. 2002. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf), 56:65-71.
9. Ambrosio MR, Franceschetti P, Bondanelli M, et al. 2002. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly. Metabolism, 51:387-93.
10. Andries M, Glintborg D, Kvistborg A, et al. 2008. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf), 68:473-80.
11. Antonijoan RM, Barbanoj MJ, Cordero JA, et al. 2004. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol, 56:471-6.
12. Ashwell SG, Bevan JS, Edwards OM, et al. 2004. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol, 150:473-80.
13. Astruc B, Marbach P, Bouterfa H, et al. 2005. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol, 45:836-44.
14. Attanasio R, Baldelli R, Pivonello R, et al. 2003b. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab, 88:5258-65.
15. Attanasio R, Epaminonda P, Motti E, et al. 2003a. Gamma-knife radiosurgery in acromegaly: A 4-year follow-up study. J Clin Endocrinol Metab, 88:3105-12.
16. Ayuk J, Clayton RN, Holder G et al. 2004. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor I concentrations predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab, 89:1613-17.
17. Baldelli R, Battista C, Leonetti F, et al. 2003. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf), 59:492-9.
18. Baldelli R, Colao A, Razzore P, et al. 2000. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab, 85:4099-103.
19. Baldelli R, Ferretti E, Jaffrain-Rea ML, et al. 1999. Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab, 84:527-32.
20. Barkan AL, Halasz I, Dornfeld KJ, et al. 1997. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab, 82:3187-91.
21. Barkan AL, Lloyd RV, Chandler WF, et al. 1988. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab, 76:1040-8.
22. Barkan AL, Stred SE, Reno K, et al. 1989. Increased growth hormone pulse frequency in acromegaly. J Clin Endocrinol Metab, 69:1225-33.
23. Barrande G, Pittino-Lungo M, Coste J, et al. 2000. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab, 85:3779-85.
24. Bates AS, Van'tHoff W, Jones JM, et al. 1993. An audit of outcome of treatment in acromegaly. Q J Med, 86:293-9.
25. Bates PR, Carson MN, Trainer PJ, et al. 2008. Wide variation in surgical outcomes for acromegaly in the UK. Clin Endocrinol (Oxf), 68:136-42.
26. Beauregard C, Truong U, Hardy J, Serri O, 2003. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf), 58:86-91.
27. Bengtsson BA, Eden S, Ernest I, et al. 1988. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med. Scand, 223:327-35.
28. Ben-Shlomo A, Melmed S. 2007. Pasireotide - a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. Drugs, 10:885-95.
29. Ben-Shlomo A, Melmed S. 2008. Acromegaly. Endocrinol Metab N Am, 27:101-22.
30. Bevan JS. 2005. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly J Clin Endocrinol Metab, 90:1856-63.
31. Bevan JS, Newell-Price J, Wass JAH, et al. 2008. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxford), 68: 343-349.
32. Bidlingmaier M, Strasburger CJ. 2007. Growth hormone assays: current methodologies and their limitations. Pituitary, 10:115-19.
33. Biermasz NR, Dekker FW, Pereira AM, et al. 2004a. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor-I measurements. J Clin Endocrinol Metab, 89:2789-96.
34. Biermasz NR, Pereira AM, Frolich M, et al. 2004c. Octreotide represses secretory-burst mass and non-pulsatile secretion but does not restore event frequency of orderly GH secretion in acromegaly. Am J Physiol Endocrinol Metab, 286:E25-E30.
35. Biermasz NR, Pereira AM, Neelis KJ, et al. 2006. The role of radiotherapy in the management of acromegaly. Expert Rev Endocrinol Metab, 1:449-60.
36. Biermasz NR, Pereira AM, Smit JW, et al. 2005a. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab, 90:2731-9.
37. Biermasz NR, Pereira AM, Smit JW, et al. 2005b. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Horm IGF Res, 15:200-6.
38. Biermasz NR, Smit JW, Pereira AM, et al. 2007. Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary, 10:237-49.
39. Biermasz NR, van Dulken H, Roelfsema F. 1999. Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab, 84:3551-5.
40. Biermasz NR, van Dulken H, Roelfsema F. 2000a. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab, 85:4596-602.
41. Biermasz NR, van Dulken H, Roelfsema F. 2000b. Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. Clin Endocrinol (Oxf), 53:321-7.
42. Biermasz NR, van Thiel SW, Pereira AM, et al. 2004b. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab, 89:5369-76.
43. Brada M, Ajithkumar TV, Minniti G, et al. 2004. Radiosurgery for pituitary adenomas. Clin Endocrinol (Oxf), 61:531-43.
44. Brada M, Ford D, Ashley S, et al. 1992. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ, 304:1343-6.
45. Brazeau P, Vale W, Burgus R, et al.1973. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science, 179:77-9.
46. Bronstein M, Musolino N, Jallad R, et al. 2005. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf), 63:514-19.
47. Cannavo S, Squadrito S, Curto L, et al. 2000. Results of a two-year treatment with slow release lanreotide in acromegaly. Horm Metab Res, 32:224-9.
48. Caron P, Beckers A, Cullen DR, et al. 2002. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab, 87:99-104.
49. Caron P, Bex M, Cullen DR, et al. 2004. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf), 60:734-40.
50. Caron P, Cogne M, Raingeard I, et al. 2006. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf), 64:209-14.
51. Caron P, Morange-Ramos I, Cogne M, et al. 1997. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab, 82:18-22.
52. Castinetti F, Taieb D, Kuhn JM, et al. 2005. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab, 90:4483-8.
53. Cerasi E, Luft R. 1964. Insulin response to glucose loading in acromegaly. Lancet, 284:769-71.
54. Chanson P, Boerlin V, Ajzenberg C, et al. 2000b. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf), 53:577-86.
55. Chanson P, Borson-Chazot F, Kuhn JM, et al. 2008. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf), doi: 10.1111/j.1365- 2265.2008.03208.x.
56. Chanson P, Leselbaum A, Blumberg J, et al. 2000a. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. Pituitary, 2:269-76.
57. Ciccarelli E, Valetto MR, Vassario E, et al. 1993. Hormonal and radiological effects of megavoltage radiotherapy in patients with growth hormonesecreting pituitary adenoma. J Endocrinol Invest, 16:565-72.
58. Clayton RN. 2003. Cardiovascular function in acromegaly. Endocr Rev, 24:272-7.
59. Clemmons DR. 2007. IGF-I assays: current assay methodologies and their limitations. Pituitary, 10:121-8.
60. Colao A, Attanasio R, Pivonello R, et al. 2006b. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.J Clin Endocrinol Metab, 91:85-92.
61. Colao A, Ferone D, Cappabianca, et al. 1997. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab, 82:3308-14.
62. Colao A, Ferone D, Lastoria S, et al. 1996. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab, 81:2356-62.
63. Colao A, Ferone D, Marzullo P, et al. 2004. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev, 25:102-52.
64. Colao A, Marzullo P, Ferone D, et al. 1999. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest, 22:40-7.
65. Colao A, Pivonello R, Auriemma RS, et al. 2006a. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab, 91:2112-18.
66. Colao A, Pivonello R, Aurriemma RS, et al. 2007. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol, 157:579-87.
67. Cozzi R, Attanasio R, Montini M, et al. 2003. Four-year treatment with octreotide-LAR in 110 acromegalic patients: the predictive value of short-term results by ROC analysis. J Clin Endocrinol Metab, 88:3090-8.
68. Cozzi R, Attanasio R, Lodrini S, et al. 2004. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf), 61:209-15.
69. Cozzi R, Barausse M, Ashnaghi D, et al. 2001. Failure of radiotherapy in acromegaly. Eur J Endocrinol, 145:717-26.
70. Cozzi R, Barausse M, Sberna M, et al. 2000. Lanreotide 60 mg, a longeracting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. Pituitary, 3:231-8.
71. Cozzi R, Dallabonzana D, Attanasio R, et al. 1999. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol, 141:267-71.
72. Danila DC, Haidar JN, Zhang X, et al. 2001. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab, 86: 2976-81.
73. De P, Rees DA, Davies N, et al. 2003. Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. J Clin Endocrinol Metab, 88:3567-72.
74. De Herder WW, Taal HR, Uitterlinden P, et al. 2005. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin-LAR in acromegaly. Eur J Endocrinol, 153:67-71.
75. Dekkers OM, Biermasz NR, Pereira AM, et al. 2008. Mortality in acromegaly: a meta-analysis. J Clin Endocrinol Metab, 93: 61-7.
76. Dowling RH, Hussaini SH, Murphy GM, Besser GM, Wass JAH. 1992. Gallstones during octreotide therapy. Metabolism, 41(Suppl 2):22-33.
77. Epaminonda R, Porretti S, Cappiello V, et al. 2001. Efficacy of radiotherapy in normalizing serum IGF-I, acid labile subunit (ALS) and IGFBP-3 levels in acromegaly. Clin Endocrinol (Oxf), 55: 183-9.
78. Ezzat S, Forster MJ, Berchtold P, et al. 1994. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore), 73:233-40.
79. Fahlbusch R, Keller B, Ganslandt O, et al. 2005. Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging. Eur J Endocrinol, 153:239-48.
80. Feenstra J, de Herder WW, ten Have SMTH, et al. 2005. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet, 365:63011-15.
81. Ferone D, Saveanu A, Culler MD, et al. 2007. Novel chimeric somatostatin analogs: facts and perspectives. Eur J Endocrinol, 156:S23-S8.
82. Florio T, Thellung S, Corsaro A, et al. 2003. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf), 59:115-28.
83. Foss MC, Saad MJ, Paccola GM, et al. 1991. Peripheral glucose metabolism in acromegaly. J Clin Endocrinol Metab, 72:1048-53.
84. Fougner SL, Borota OC, Berg JP, et al. 2008. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf), 68:458-65.
85. Freda PU. 2003. How effective are current therapies for acromegaly? Growth Horm IGF Res, 13(Suppl A):S144-S51.
86. Freda PU, Katznelson L, van der Lely AJ, et al. 2005. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab, 90:4465-73.
87. Freda PU, Wardlaw SL, Post KD, et al. 1998. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg, 89:353-8.
88. Gilbert JA, Miell JP, Chambers, et al. 2005. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clin Endocrinol (Oxf), 620:742-7.
89. Giusti M, Ciccarelli E, Dallabonzana D, et al. 1997. Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest, 27:277-84.
90. Giustina A, Barkan A, Casanueva FF, et al. 2000. Consensus. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab, 85:526-9.
91. Greenman Y, Tordjman K, Kisch E, et al. 1995. Relative sparing of anterior pituitary function in patients with growth hormonesecreting macroadenomas: comparison with nonfunctioning macroadenomas. J Clin Endocrinol Metab, 80:1577-83.
92. Gullu S, Keles H, Delibasi T, et al. 2004. Remission criteria for the follow-up of patients with acromegaly. Eur J Endocrinol, 150:465-71.
93. Gutt B, Bidlingmaier M, Kretschmar K, et al. 2005. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes, 113:139-44.
94. Hansen I, Isalikian E, Beaufrere B, et al. 1986. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol, 250: E269-E73.
95. Harris PE, D'Souza G, Good AJ, et al. 2007. Treatm ent with pegvisomant alone compared to combination therapy with pegvisomant/octreotide LAR in acromegaly. Abstract OR 53-3.The Endocrine Society Annual Meeting, Toronto, Ontario, Canada, June 2-5, 2007.
96. Heron I, Thomas F, Dero M, et al. 1993. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab, 76:721-7.
97. Ho KY, Weisberger AJ. 1994. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol (Oxf), 41:75-83.
98. Hofland LJ, Lamberts SWJ. 2003. The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance. Endocr Rev, 24:28-47.
99. Holdaway IM. 2007. Excess mortality in acromegaly. Horm Res, (Suppl 5):166-72.
100. Holdaway IM, Rajasoorya RC, Gamble GD. 2004. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab, 89:667-74.
101. Hradec J, Krai J, Janota T, et al. 1999. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol, 83:1506-9.
102. Hua SC, Yan YH, Chang TC. 2006. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol, 155:831-7.
103. Jaffe CA, Barkan AL. 1992. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am, 21:713-35.
104. Jenkins PJ, Besser M. 2001. Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab, 86:2935-41.
105. Johnson MR, Chowdrey HS, Thomas F, et al. 1994. Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur J Endocrinol, 130:229-34.
106. Jørgensen JOL, Feldt-Rasmusen U, Frystyk J, et al. 2005. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab, 90:5627-31.
107. Kaltsas GA, Isidori AM, Florakis D, et al. 2001. Predictors of outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab, 86:1645-52.
108. Karavitaki N, Botusan I, Radian S, et al. 2005. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol (Oxf), 62:282-8.
109. Karavitaki N, Turner HE, Adams CB, et al. 2007. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf), doi: 10.1111/j.1365-2265.2007.03139.x.
110. Kasayama S, Otsuki M, Tagaki M, et al. 2000. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf), 52:549-55.
111. Kauppinen-Makelin R, Sane T, Reunanen A, et al. 2005. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab, 90:4081-6.
112. Kendall-Taylor P, Miller M, Gebbie J, et al. 2000. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly. Pituitary, 3:61-5.
113. Krantic S, Goddard I, Saveanu A, et al. 2004. Novel modalities of somatostatin actions. Eur J Endocrinol, 151:643-55.
114. Kreutzer J, Vance ML, Lopes MB, et al. 2001. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab, 86:4072-7.
115. Koop BL, Harris AG, Ezzat S. 1994. Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol, 130:581-6.
116. Kristof RA, Stoffel-Wagner B, Klingmuller D, et al. 1999. Does octreotide treatment improve the surgical results of macroadenomas in acromegaly? A randomized study. Acta Neurochirg, 141:399-405.
117. Kuhn JM, Basin C, Mollard M, et al. 1992. Effects of the new somatostatin analogue (BIM 23014) on blood glucose homeostasis in normal men. Eur J Clin Invest, 22:793-9.
118. Kuhn JM, Legrand A, Ruiz JM, et al. 1994. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol, 38:213-19.
119. Lamberts SW, Van der Lely AJ, De Herder WW, et al. 1996. Octreotide. N Engl J Med, 334:246-54.
120. Landolt AM, Haller D, Lomax N, et al. 1998. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg, 88:1002-8.
121. Le Roith D, Bondy C, Yakar S, et al. 2001. The somatomedin hypothesis. Endocr Rev, 22:53-74.
122. Loeper S, Ezzat S. 2008. Acromegaly: Re-thinking the cancer risk. Rev Endocr Metab Disord, 9:41-58.
123. Long H, Beauregard H, Somma M, et al. 1996. Surgical outcome after repeated transsphenoidal surgery in acromegaly. J Neurosurg, 85:239-47.
124. Lucas T, Astorga R, Catala M, et al. 2003. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf), 58:471-81.
125. Lucas T, Astorga R; Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly. 2006. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf), 65:320-6.
126. Lüdecke DK, Abe T. 2006. Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1000 operations. Neuroendocrinology, 83:230-9.
127. Mahmoud-Ahmed AS, Suh JH, Mayberg MR. 2001. Gamma knife radiosurgery in the management of patients with acromegaly: a review. Pituitary, 4:223-30.
128. Maison P, Tropeano A-I, Macquin-Mavier I, et al. 2007. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab, 92:1743-7.
129. Marcou Y, Plowman PN. 2000. Stereotactic radiosurgery for pituitary adenomas. Trends Endocrinol Metab, 11: 132-7.
130. Marek J, Hana V, Krsek M, et al. 1994. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol, 131:20-26.
131. Matta MP, Couture E, Cazals L, et al. 2008. Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol, 158:305-10.
132. Melmed S. 2001. Acromegaly and cancer: not a problem? J Clin Endocrinol Metab, 86:2929-34.
133. Melmed S. 2006. Acromegaly. N Engl J Med, 355:2558-73.
134. Melmed S, Casanueva FF, Cavagni T, et al. 2002. Consensus. Guidelines for acromegaly management. J Clin Endocrinol Metab, 87:4054-8.
135. Melmed S, Sternberg R, Cool D, et al. 2005. Clinical review: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab, 90:4405-10.
136. Mestron A, Webb SM, Astorga R, et al. 2004. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol, 151:439-46.
137. Minniti G, Jaffrain-Rea ML, Osti M, et al. 2005. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf), 62:210-16.
138. Morange I, De Boisvilliers F, Chanson P, et al. 1994. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab, 79:145-51.
139. Murray RD, Kim K, Ren S-G. 2004. Central and peripheral actions of somatostatin on growth hormone-IGF-I axis. J Clin Invest, 114:349-56.
140. Neggers JCM, van Aken MO, Janssen JAM, et al. 2007. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab, 92:4598-601.
141. Newman CB, Melmed S, Snyder PJ, et al. 1995. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study. J Clin Endocrinol Metab, 80:2768-75.
142. Nomikos P, Buchfelder M, Fahlbusch R. 2005. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol, 152:379-87.
143. Olias G, Viollet C, Kusserow H, et al. 2004. Regulation and function of somatostatin receptors. J Neurochem, 89:1057-91.
144. Orme S, McNally RJ, Cartwright RA, et al. 1998. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab, 83:2730-4.
145. Patel YC. 1999. Somatostatin and its receptor family. Front Neuroendocrinol, 20:157-98.
146. Pereira AM, Biermaz NR, Roelfsema F, et al. 2005. Pharmacologic therapies for acromegaly. Treat Endocrinol, 4:43-53.
147. Pereira AM, Van Thiel SW, Lindner JR, et al. 2004. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab, 89:71-5.
148. Pokrajac A, Claridge AG, Abdoul Shakoor SK, et al. 2006. The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. Eur J Endocrinol, 154:267-74.
149. Powell JS, Wardlaw SL, Post KD, et al. 2000. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab, 85:2068-71.
150. Razzore P, Colao A, Baldelli R, et al. 1999. Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. Clin Endocrinol (Oxf), 51:159-64.
151. Reichlin S. 1983. Somatostatin. N Engl J Med, 309:1495-501.
152. Renehan AG, Shalet SM. 2002. Acromegaly and colorectal cancer: risk assessment should be based on population-based studies. J Clin Endocrinol Metab, 87:1909.
153. Ritchie CM, Atkinson AB, Kennedy AL, et al.1990. Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Med J, 59:55-62.
154. Roberts BK, Ouyang DL, Shivanand PL, et al. 2007. Efficacy and safety of cyberknife radiosurgery for acromegaly. Pituitary, 10:19-25.
155. Roelfsema F, Biermasz NR, Pereira AM, et al. 2006. Nanomedicines in the treatment of acromegaly: focus on pegvisomant. Int J Nanomedicine, 1:385-98.
156. Ronchi CL, Boschetti M, Degli Uberti EC, et al. 2007. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf), 67:512-19.
157. Ronchi CL, Orsi E, Giavoli C, et al. 2003. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J Endocrinol Invest, 26:533-8.
158. Ronchi CL, Rizzo E, Lania AG, et al. 2008. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol, 158:19-25.
159. Rowles SV, Prieto L, Badia X, et al. 2005. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab, 90:3337-41.
160. Schade R, Andersohn F, Suisse S, et al. 2007. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med, 356:29-38.
161. Schloffer H. 1907. Erfolgreiche Operation eines Hypophysentumors auf nasalem Wege. Wien Klin Wochenschr, 20:621-4.
162. Schreiber I, Buchfelder M, Droste M, et al. 2007. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol, 156:75-82.
163. Serri O, Brazeau P, Kachra Z, et al.1992. Octreotide inhibits insulin-like growth factor-I hepatic gene expression in hypophysectomized rat: evidence for a direct and indirect mechanism of action. Endocrinology, 130:1816-21.
164. Sheehan JP, Niranjan A, Sheehan JM, et al. 2005. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and the role in the neurosurgical treatment armamentarium. J Neurosurg, 102:678-91.
165. Shimon I, Cohen ZR, Ram Z, et al. 2001. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery, 48:1239-43.
166. Sjogren K, Liu JL, Blad K, et al. 1999. Liver-derived insulin-like growth factor I (IGF-I) is the principle source of IGF-I in blood but it is not required for postnatal body growth in mice. Proc Natl Acad Sci USA, 96:7088-92.
167. Sonino N, Scarpa E, Paoletta A, et al. 1999. Slow-release lanreotide treatment in acromegaly: effects on quality of life. Psychother Psychosom, 68:165-7.
168. Sonksen PH, Greenwood FC, Ellis JP, et al. 1967. Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol Metab, 27:1418-30.
169. Steffin B, Gutt B, Bidlingmaier M, et al. 2006. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol, 155:73-8.
170. Stevenaert A, Beckers A. 1996. Presurgical octreotide treatment in acromegaly. Metabolism, 45(Suppl 1):72-4.
171. Suliman M, Jenkins R, Ross R, et al. 1999. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J Endocrinol Invest, 22:409-18.
172. Swaeringen B, Barker FG, Katznelson L, et al. 1998. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab, 83:3419-26.
173. Taboada GF, Luque RM, Neto LV, et al. 2008. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol, 158:295-303.
174. Thalassinos NC, Tsagarakis S, Ioannides G, et al. 1998. Megavoltage pituitary irradiation lowers, but seldom leads to safe GH levels in acromegaly: a long-term follow-up study. Eur J Endocrinol, 138:160-3.
175. Thomale UW, Stover JF, Unterberg AW. 2005. The use of neuronavigation in transnasal transsphenoidal pituitary surgery. Zentralbl Neurochir, 66:126-32.
176. Trainer PJ, Drake WM, Katznelson L, et al. 2000. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med, 342:1171-7.
177. Turner HE, Vadivale A, Keenan J, Wass JA. 1999. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf), 51:275-280.
178. Valéry C, Paternostre M, Robert B, et al. 2003. Biomimetic organization: Octapeptide self-assembly into nanotubes of viral capsid-like dimension. Proc Natl Acad Sci USA, 100:10258-62.
179. Valéry C, Pouget E, Pandit A, et al. 2008. Molecular origin of the selfassembly of lanreotide into nanotubes: a mutational approach. Biophys J, 94:1782-95.
180. Van den Berg G, Frolich M, Veldhuis JD, et al. 1994. Growth hormone secretion in recently operated acromegalic patients. J Clin Endocrinol Metab, 79:1706-15.
181. Van den Berg G, Pincus SM, Frolich M, et al.1998. Reduced disorderliness of growth hormone release in biochemically inactive acromegaly after pituitary surgery. Eur J Endocrinol, 138:164-9.
182. Van der Hoek J, Lamberts SW, Hofland LJ. 2004. The role of somatostatin analogs in Cushing's disease. Pituitary, 7:257-64.
183. Van der Hoek J, van der Lely AJ, Feelders RA, et al. 2005. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol (Oxf), 63:176-84.
184. Van der Lely AJ, Hutson RK, Trainer PJ, et al. 2001. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet, 358:1754-9.
185. Van Thiel SW, Bax JJ, Biermasz NR, et al. 2005. Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. Eur J Endocrinol, 153:231-8.
186. Van Thiel SW, Romijn JA, Biermasz NR, et al. 2004. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol, 150:489-95.
187. Verhelst JA, Pedroncelli AM, Abs R, et al. 2000. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol, 143:577-84.
188. Wasko R, Jankowska A, Kotwicka M, et al. 2003. Effects of treatment with somatostatin analogues on the occurrence of apoptosis in somatotropinomas. Neuro Endocrinol Lett, 24:334-8.
189. Wass JA, 2003. Radiotherapy in acromegaly: a protagonist's viewpoint. Clin Endocrinol (Oxf), 58:128-31.
190. Wass JA, Cudworth AG, Bottazzo GF, et al. 1980. An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clin Endocrinol (Oxf), 12:53-59.
191. Wright AD, Hill DM, Lowy C, et al. 1970. Mortality in acromegaly. Q J Med, 39:1-16.
192. Zatelli MC, Ambrosio MR, Bondanelli M, et al. 2007. Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds. Eur J Endocrinol, 156:S29-S35.